Q3UPF5
PR
Gene name |
Zc3hav1 |
Protein name |
Zinc finger CCCH-type antiviral protein 1 |
Names |
ADP-ribosyltransferase diphtheria toxin-like 13, ARTD13, Inactive Poly [ADP-ribose] polymerase 13, PARP13 |
Species |
Mus musculus (Mouse) |
KEGG Pathway |
mmu:78781 |
EC number |
|
Protein Class |
|
Descriptions
The autoinhibited protein was predicted that may have potential autoinhibitory elements via cis-regPred.
Autoinhibitory domains (AIDs)
Target domain |
|
Relief mechanism |
|
Assay |
cis-regPred |
Accessory elements
No accessory elements
Autoinhibited structure
Activated structure
4 structures for Q3UPF5
| Entry ID | Method | Resolution | Chain | Position | Source |
|---|---|---|---|---|---|
| 6L1W | X-ray | 219 A | A | 1-227 | PDB |
| 7SZ2 | X-ray | 220 A | A/B | 592-789 | PDB |
| 7SZ3 | X-ray | 220 A | A/B | 592-789 | PDB |
| AF-Q3UPF5-F1 | Predicted | AlphaFoldDB |
57 variants for Q3UPF5
| Variant ID(s) | Position | Change | Description | Diseaes Association | Provenance |
|---|---|---|---|---|---|
| rs3388791030 | 13 | I>F | No | EVA | |
| rs3388815806 | 37 | L>F | No | EVA | |
| rs3396656045 | 47 | D>V | No | EVA | |
| rs3388815940 | 68 | T>I | No | EVA | |
| rs3388802249 | 72 | V>I | No | EVA | |
| rs3388821331 | 133 | E>D | No | EVA | |
| rs3396719515 | 195 | D>A | No | EVA | |
| rs3388817938 | 208 | S>R | No | EVA | |
| rs3388815908 | 215 | I>T | No | EVA | |
| rs229963616 | 282 | P>S | No | EVA | |
| rs3388809796 | 289 | D>E | No | EVA | |
| rs216775258 | 301 | D>E | No | EVA | |
| rs238311225 | 384 | E>K | No | EVA | |
| rs258631343 | 396 | I>V | No | EVA | |
| rs248423235 | 441 | A>T | No | EVA | |
| rs249089563 | 472 | G>S | No | EVA | |
| rs230182274 | 475 | G>S | No | EVA | |
| rs250410829 | 478 | Q>H | No | EVA | |
| rs3388802293 | 489 | S>N | No | EVA | |
| rs13462128 | 525 | T>N | No | EVA | |
| rs3396828839 | 530 | Q>AAYCCPVQE* | No | EVA | |
| rs3388817804 | 543 | S>P | No | EVA | |
| rs3388824406 | 546 | H>Y | No | EVA | |
| rs216659056 | 548 | V>I | No | EVA | |
| rs3388823114 | 555 | G>V | No | EVA | |
| rs256788926 | 557 | S>N | No | EVA | |
| rs216408431 | 559 | T>A | No | EVA | |
| rs3396244605 | 582 | Y>* | No | EVA | |
| rs3396244607 | 586 | Y>* | No | EVA | |
| rs263365046 | 592 | S>T | No | EVA | |
| rs3388824456 | 636 | W>S | No | EVA | |
| rs3388822053 | 657 | I>F | No | EVA | |
| rs3388830677 | 666 | F>L | No | EVA | |
| rs38504197 | 717 | S>G | No | EVA | |
| rs3388791060 | 738 | G>E | No | EVA | |
| rs3388824422 | 751 | L>I | No | EVA | |
| rs3388823106 | 807 | Q>K | No | EVA | |
| rs258754561 | 810 | A>T | No | EVA | |
| rs225473097 | 815 | S>P | No | EVA | |
| rs234491233 | 817 | E>G | No | EVA | |
| rs233668994 | 825 | N>S | No | EVA | |
| rs3388815877 | 858 | W>S | No | EVA | |
| rs3388812819 | 859 | D>V | No | EVA | |
| rs3388822050 | 863 | R>G | No | EVA | |
| rs38235453 | 903 | I>T | No | EVA | |
| rs3388815862 | 903 | I>V | No | EVA | |
| rs864262788 | 905 | Y>N | No | EVA | |
| rs264421875 | 915 | N>S | No | EVA | |
| rs36492446 | 920 | H>L | No | EVA | |
| rs36492446 | 920 | H>R | No | EVA | |
| rs255573746 | 922 | H>Y | No | EVA | |
| rs3396406922 | 925 | L>H | No | EVA | |
| rs3396254942 | 926 | E>V | No | EVA | |
| rs233020426 | 934 | R>G | No | EVA | |
| rs3388806521 | 934 | R>I | No | EVA | |
| rs213839268 | 934 | R>S | No | EVA | |
| rs247440776 | 939 | D>G | No | EVA |
No associated diseases with Q3UPF5
5 regional properties for Q3UPF5
| Type | Name | Position | InterPro Accession |
|---|---|---|---|
| domain | Zinc finger, CCCH-type | 173 - 194 | IPR000571 |
| domain | WWE domain | 684 - 771 | IPR004170 |
| domain | Poly(ADP-ribose) polymerase, catalytic domain | 805 - 946 | IPR012317 |
| domain | ZAP, zinc finger | 143 - 170 | IPR040954 |
| domain | ZAP, helix turn helix N-terminal domain | 5 - 66 | IPR041360 |
Functions
3 GO annotations of cellular component
| Name | Definition |
|---|---|
| cytoplasm | The contents of a cell excluding the plasma membrane and nucleus, but including other subcellular structures. |
| cytosol | The part of the cytoplasm that does not contain organelles but which does contain other particulate matter, such as protein complexes. |
| nucleus | A membrane-bounded organelle of eukaryotic cells in which chromosomes are housed and replicated. In most cells, the nucleus contains all of the cell's chromosomes except the organellar chromosomes, and is the site of RNA synthesis and processing. In some species, or in specialized cell types, RNA metabolism or DNA replication may be absent. |
5 GO annotations of molecular function
| Name | Definition |
|---|---|
| DEAD/H-box RNA helicase binding | Binding to a DEAD/H-box RNA helicase. |
| identical protein binding | Binding to an identical protein or proteins. |
| metal ion binding | Binding to a metal ion. |
| NAD+ ADP-ribosyltransferase activity | Catalysis of the reaction: NAD+ + (ADP-D-ribosyl)(n)-acceptor = nicotinamide + (ADP-D-ribosyl)(n+1)-acceptor. |
| RNA binding | Binding to an RNA molecule or a portion thereof. |
14 GO annotations of biological process
| Name | Definition |
|---|---|
| cellular response to exogenous dsRNA | Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an exogenous double-stranded RNA stimulus. |
| cellular response to virus | Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus from a virus. |
| defense response to virus | Reactions triggered in response to the presence of a virus that act to protect the cell or organism. |
| innate immune response | Innate immune responses are defense responses mediated by germline encoded components that directly recognize components of potential pathogens. |
| negative regulation of viral genome replication | Any process that stops, prevents, or reduces the frequency, rate or extent of viral genome replication. |
| positive regulation of ATP-dependent activity | Any process that activates or increases the rate of an ATP-dependent activity. |
| positive regulation of I-kappaB kinase/NF-kappaB signaling | Any process that activates or increases the frequency, rate or extent of I-kappaB kinase/NF-kappaB signaling. |
| positive regulation of interferon-alpha production | Any process that activates or increases the frequency, rate, or extent of interferon-alpha production. |
| positive regulation of interferon-beta production | Any process that activates or increases the frequency, rate, or extent of interferon-beta production. |
| positive regulation of mRNA catabolic process | Any process that increases the rate, frequency, or extent of a mRNA catabolic process, the chemical reactions and pathways resulting in the breakdown of RNA, ribonucleic acid, one of the two main type of nucleic acid, consisting of a long, unbranched macromolecule formed from ribonucleotides joined in 3',5'-phosphodiester linkage. |
| positive regulation of RIG-I signaling pathway | Any process that activates or increases the frequency, rate or extent of RIG-I signaling pathway. |
| positive regulation of type I interferon production | Any process that activates or increases the frequency, rate, or extent of type I interferon production. Type I interferons include the interferon-alpha, beta, delta, episilon, zeta, kappa, tau, and omega gene families. |
| regulation of defense response to virus by host | Any host process that modulates the frequency, rate, or extent of the antiviral response of a host cell or organism. |
| response to virus | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus from a virus. |
3 homologous proteins in AiPD
| 10 | 20 | 30 | 40 | 50 | 60 |
| MTDPEVFCFI | TKILCAHGGR | MTLEELLGEI | SLPEAQLYEL | LKAAGPDRFV | LLETGDQAGI |
| 70 | 80 | 90 | 100 | 110 | 120 |
| TRSVVATTRA | RVCRRKYCQR | PCDSLHLCKL | NLLGRCHYAQ | SQRNLCKYSH | DVLSEQNFQV |
| 130 | 140 | 150 | 160 | 170 | 180 |
| LKNHELSGLN | QEELAVLLVQ | SDPFFMPEIC | KSYKGEGRKQ | ICGQPQPCER | LHICEHFTRG |
| 190 | 200 | 210 | 220 | 230 | 240 |
| NCSYLNCLRS | HNLMDRKVLA | IMREHGLSSD | VVQNIQDICN | NKHTRRNPPS | MRAPHPHRRG |
| 250 | 260 | 270 | 280 | 290 | 300 |
| GAHRDRSKSR | DRFHHNSLEV | LSTVSPLGSG | PPSPDVTGCK | DPLEDVSADV | TQKFKYLGTQ |
| 310 | 320 | 330 | 340 | 350 | 360 |
| DRAQLSSVSS | KAAGVRGPSQ | MRASQEFLED | GDPDGLFSRN | RSDSSTSRTS | AAGFPLVAAQ |
| 370 | 380 | 390 | 400 | 410 | 420 |
| RNEAGAMKMG | MPSGHHVEVK | GKNEDIDRVP | FLNSYIDGVT | MEEATVSGIL | GKRATDNGLE |
| 430 | 440 | 450 | 460 | 470 | 480 |
| EMILSSNHQK | SVAKTQDPQT | AGRITDSGQD | TAFLHSKYEE | NPAWPGTSTH | NGPNGFSQIM |
| 490 | 500 | 510 | 520 | 530 | 540 |
| DETPNVSKSS | PTGFGIKSAV | TGGKEAVYSG | VQSLRSHVLA | MPGETTTPVQ | GSNRLPPSPL |
| 550 | 560 | 570 | 580 | 590 | 600 |
| SSSTSHRVAA | SGSPGKSSTH | ASVSPASEPS | RMMMMMSDPA | EYSLCYIVNP | VSPRMDDHGL |
| 610 | 620 | 630 | 640 | 650 | 660 |
| KEICLDHLYR | GCQQVNCNKN | HFHLPYRWQL | FILPTWMDFQ | DMEYIERAYC | DPQIEIIVIE |
| 670 | 680 | 690 | 700 | 710 | 720 |
| KHRINFKKMT | CDSYPIRRLS | TPSFVEKTLN | SVFTTKWLWY | WRNELNEYTQ | YGHESPSHTS |
| 730 | 740 | 750 | 760 | 770 | 780 |
| SEINSAYLES | FFHSCPRGVL | QFHAGSQNYE | LSFQGMIQTN | IASKTQRHVV | RRPVFVSSKD |
| 790 | 800 | 810 | 820 | 830 | 840 |
| VEQKRRGPDH | QPVMPQADAL | TLFSSPQRNA | STVSSNEYEF | IELNNQDEEY | AKISEQFKAS |
| 850 | 860 | 870 | 880 | 890 | 900 |
| MKQFKIVTIK | RIWNQKLWDT | FERKKQKMKN | KTEMFLFHAV | GRIHMDYICK | NNFEWILHGN |
| 910 | 920 | 930 | 940 | ||
| REIRYGKGLC | WRRENCDSSH | AHGFLEMPLA | SLGRTASLDS | SGLQRK |